ES2531629T3 - Anticuerpos anti-MIF - Google Patents

Anticuerpos anti-MIF Download PDF

Info

Publication number
ES2531629T3
ES2531629T3 ES08869976.4T ES08869976T ES2531629T3 ES 2531629 T3 ES2531629 T3 ES 2531629T3 ES 08869976 T ES08869976 T ES 08869976T ES 2531629 T3 ES2531629 T3 ES 2531629T3
Authority
ES
Spain
Prior art keywords
mif
antibody
once
antigen binding
encompasses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08869976.4T
Other languages
English (en)
Inventor
Randolf Kerschbaumer
Friedrich Scheiflinger
Manfred Rieger
Michael Thiele
C. Geert Mudde
Juergen Muellberg
Rene Hoet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Dyax Corp
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc, Dyax Corp filed Critical Baxter Healthcare SA
Application granted granted Critical
Publication of ES2531629T3 publication Critical patent/ES2531629T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpo monoclonal o parte de unión a antígeno del mismo que se une específicamente a la región que se abarca los aa 50-68 o la región que abarca los aa 86-102 de MIF humano, e inhibe la función biológica de MIF humano.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
5
15
25
35
45
55
65
E08869976
27-02-2015
fosfato, dextrosa, glicerol, etanol y similares, así como combinaciones de los mismos. En muchos casos, será preferible incluir agentes isotónicos, por ejemplo, azúcares, polialcoholes tales como manitol, sorbitol, o cloruro de sodio en la composición. Ejemplos adicionales de sustancias farmacéuticamente aceptables son agentes humectantes o cantidades menores de sustancias auxiliares tales como agentes humectantes o emulsionantes, conservantes o tampones, que potencian la vida útil de almacenamiento o eficacia del anticuerpo.
El anticuerpo anti-MIF de la invención y las composiciones farmacéuticas que lo comprenden pueden administrarse en combinación con uno o más de otros agentes terapéuticos, de diagnóstico o profilácticos. Los agentes terapéuticos adicionales incluyen otros agentes antineoplásicos, antitumorales, antiangiogénicos, quimioterápicos o esteroides, dependiendo de la enfermedad que va a tratarse.
Las composiciones farmacéuticas de esta invención pueden estar en una variedad de formas, por ejemplo, formas de dosificación líquidas, semisólidas y sólidas, tales como disoluciones líquidas (por ejemplo, disoluciones inyectables y para infusión), dispersiones o suspensiones, comprimidos, pastillas, polvos, liposomas y supositorios. La forma preferida depende de la aplicación terapéutica y el modo de administración previstos. Composiciones preferidas típicas están en forma de disoluciones inyectables o para infusión, tales como composiciones similares a las usadas para la inmunización pasiva de seres humanos. El modo de administración preferido es parenteral (por ejemplo, intravenoso, subcutáneo, intraperitoneal, intramuscular). En una realización preferida, el anticuerpo se administra mediante infusión o inyección intravenosa. En otra realización preferida, el anticuerpo se administra mediante inyección intramuscular o subcutánea. Tal como apreciará el experto en la técnica, la vía y/o el modo de administración variarán dependiendo de los resultados deseados.
El anticuerpo anti-MIF puede administrarse una vez, pero más preferiblemente se administra múltiples veces. Por ejemplo, el anticuerpo puede administrarse desde tres veces al día hasta una vez cada seis meses o más. La administración puede realizarse en un programa tal como de tres veces al día, dos veces al día, una vez al día, una vez cada dos días, una vez cada tres días, una vez a la semana, una vez cada dos semanas, una vez cada mes, una vez cada dos meses, una vez cada tres meses y una vez cada seis meses.
La invención también abarca el uso de un anticuerpo anti-MIF o un fragmento de unión a antígeno del mismo, en la fabricación de un medicamento para el tratamiento de enfermedades inmunológicas tales como enfermedades inflamatorias y trastornos hiperproliferativos.
La invención abarca además un anticuerpo anti-MIF o un fragmento de unión a antígeno del mismo, para su uso en el tratamiento de enfermedades inmunológicas tales como enfermedades inflamatorias y trastornos hiperproliferativos.
La invención también abarca un anticuerpo anti-MIF o un fragmento de unión a antígeno del mismo, para su uso en métodos de diagnóstico. En una realización, el anticuerpo anti-MIF o parte de unión a antígeno del mismo puede usarse para detectar MIF humano en una muestra biológica.
Los anticuerpos anti-MIF o las partes de unión a antígeno de los mismos también pueden usarse para determinar el nivel de MIF en superficie celular en un tejido o en células derivadas a partir del tejido. En algunas realizaciones, el tejido es tejido enfermo. Entonces puede usarse el tejido en un inmunoensayo para determinar, por ejemplo, niveles de MIF total, niveles de MIF en superficie celular o ubicación de MIF.
La invención se refiere además a kits que comprenden un anticuerpo anti-MIF o una parte de unión a antígeno de la invención o una composición farmacéutica que comprende un anticuerpo o una parte de este tipo. Un kit puede incluir, además del anticuerpo o la composición farmacéutica, agentes de diagnóstico o terapéuticos. Un kit también puede incluir instrucciones para su uso en un método de diagnóstico o terapéutico.
La invención se refiere además a un procedimiento para la identificación de anticuerpos anti-MIF que pueden inhibir la función biológica de MIF humano e inducir un efecto beneficioso en un modelo animal llevando a cabo las siguientes etapas:
a) seleccionar un anticuerpo que se une a MIF activo y no se une a MIF no activo,
b) someter a prueba dicho anticuerpo en ensayos in vitro, tales como ensayo de anulación de glucocorticoides (GCO) o ensayos de proliferación celular,
c) seleccionar un anticuerpo que inhibe GCO y/o la proliferación celular.
Los resultados han mostrado que un anticuerpo anti-MIF que sólo se une a MIF activo y no se une a MIF no activo e inhibe además GCO y/o la proliferación celular induce un efecto beneficioso en un modelo animal (por ejemplo, el ejemplo 6).
La presente invención se ilustrará adicionalmente mediante los siguientes ejemplos, sin ninguna limitación a los
9
imagen8
imagen9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
    imagen2
ES08869976.4T 2008-01-04 2008-12-30 Anticuerpos anti-MIF Active ES2531629T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1898808P 2008-01-04 2008-01-04
US18988P 2008-01-04
US9468508P 2008-09-05 2008-09-05
US94685P 2008-09-05
PCT/EP2008/011146 WO2009086920A1 (en) 2008-01-04 2008-12-30 Anti mif antibodies

Publications (1)

Publication Number Publication Date
ES2531629T3 true ES2531629T3 (es) 2015-03-18

Family

ID=40535633

Family Applications (3)

Application Number Title Priority Date Filing Date
ES14163839.5T Active ES2623653T3 (es) 2008-01-04 2008-12-30 Anticuerpos anti-MIF
ES08869976.4T Active ES2531629T3 (es) 2008-01-04 2008-12-30 Anticuerpos anti-MIF
ES16183733T Active ES2791333T3 (es) 2008-01-04 2008-12-30 Anticuerpos anti-MIF para su uso en el tratamiento de enfermedades inflamatorias

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES14163839.5T Active ES2623653T3 (es) 2008-01-04 2008-12-30 Anticuerpos anti-MIF

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16183733T Active ES2791333T3 (es) 2008-01-04 2008-12-30 Anticuerpos anti-MIF para su uso en el tratamiento de enfermedades inflamatorias

Country Status (22)

Country Link
US (3) US20090220521A1 (es)
EP (4) EP3118223B8 (es)
JP (1) JP5502752B2 (es)
KR (2) KR101654678B1 (es)
CN (2) CN103724430B (es)
AU (1) AU2008346517B2 (es)
BR (1) BRPI0821682A2 (es)
CA (1) CA2711029A1 (es)
CY (1) CY1117302T1 (es)
DK (1) DK2231707T3 (es)
ES (3) ES2623653T3 (es)
HR (1) HRP20150224T1 (es)
IL (1) IL206715A (es)
MX (1) MX2010007406A (es)
NZ (3) NZ611117A (es)
PL (2) PL2231707T3 (es)
PT (1) PT2231707E (es)
RS (1) RS53906B1 (es)
RU (2) RU2509777C2 (es)
SI (1) SI2231707T1 (es)
WO (1) WO2009086920A1 (es)
ZA (1) ZA201004973B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2231707T3 (pl) * 2008-01-04 2015-05-29 Baxalta Inc Przeciwciała przeciwko MIF
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
JP2014530361A (ja) * 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ Ｃｈｏ−ｍｉｆ遺伝子およびタンパク質の特性評価およびその使用
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
AU2013203957B9 (en) * 2012-04-16 2015-10-15 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
CN105452867A (zh) 2012-07-10 2016-03-30 巴克斯特保健股份有限公司 抗-mif的免疫组织化学
CA2893249A1 (en) * 2012-12-07 2014-06-12 Baxter International Inc. Anti-mif antibody cell migration assay
AU2015206178A1 (en) * 2014-01-03 2016-07-07 Baxalta GmbH Anti-MIF immunohistochemistry
US10626166B2 (en) 2014-08-22 2020-04-21 Baxalta Incorporated Detection of CHO-MIF contaminations
EP3277718B1 (en) 2015-03-31 2021-03-24 Baxalta GmbH Dosage regimen for anti-mif antibodies
EP3298039A1 (en) 2015-05-18 2018-03-28 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
CN109868311B (zh) * 2017-12-01 2023-10-20 上海市精神卫生中心 Mif及其预测二代抗精神病药物诱导的代谢不良反应的应用
KR20210018800A (ko) 2018-06-07 2021-02-18 온코원 리서치 앤드 디벨롭먼트 게엠베하 암 치료를 위한 항-oxMIF/항-CD3 항체
EP3757252B1 (en) 2019-06-28 2022-03-30 Walter Ag A coated cutting tool
JP2023504620A (ja) 2019-12-06 2023-02-06 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物
AU2021354917A1 (en) * 2020-10-02 2023-05-18 Oncoone Research & Development Gmbh IMPROVED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY
JP2024505963A (ja) * 2021-02-03 2024-02-08 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗ｏｘＭＩＦ放射性免疫コンジュゲート
ES3038265T3 (en) 2021-09-03 2025-10-10 Oncoone Res & Development Gmbh Improved fc silenced anti-oxmif antibodies with reduced aggregation potential and reduced hydrophobicity
US20250213710A1 (en) * 2022-01-10 2025-07-03 Phenomic Ai Anti-collagen triple helix repeat containing 1 (cthrc1) antibodies and methods of using the same
CN114573693A (zh) * 2022-04-25 2022-06-03 中国人民解放军陆军军医大学 一种听觉发育中免疫调节分子mif抗体制备方法
CN115814069B (zh) * 2022-10-31 2023-07-21 四川大学华西医院 Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途
JP2026507847A (ja) 2023-03-03 2026-03-06 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 過剰増殖性障害のプレターゲティングのための二重特異性抗腫瘍抗原／抗ｈｓｇ抗体の改善
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025171411A1 (en) * 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
US6030615A (en) * 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
JPH0977799A (ja) * 1995-09-13 1997-03-25 Sapporo Immuno Diagnostic Lab:Kk ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
DK1156823T3 (da) * 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
AU2001238677A1 (en) * 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
PL2231707T3 (pl) * 2008-01-04 2015-05-29 Baxalta Inc Przeciwciała przeciwko MIF

Also Published As

Publication number Publication date
MX2010007406A (es) 2010-10-05
EP3118223B1 (en) 2020-02-19
CY1117302T1 (el) 2017-04-26
HK1147762A1 (en) 2011-08-19
RU2010132647A (ru) 2012-02-10
EP2754671B1 (en) 2016-12-21
SI2231707T1 (sl) 2015-04-30
CN101983207A (zh) 2011-03-02
NZ586600A (en) 2012-05-25
RU2509777C2 (ru) 2014-03-20
DK2231707T3 (en) 2015-03-02
EP3118223A1 (en) 2017-01-18
EP2548890A1 (en) 2013-01-23
BRPI0821682A2 (pt) 2015-06-16
HRP20150224T1 (xx) 2015-06-05
JP5502752B2 (ja) 2014-05-28
EP2231707B1 (en) 2014-12-24
AU2008346517A1 (en) 2009-07-16
US20100260768A1 (en) 2010-10-14
CA2711029A1 (en) 2009-07-16
NZ611117A (en) 2014-10-31
PL2231707T3 (pl) 2015-05-29
WO2009086920A1 (en) 2009-07-16
ES2623653T3 (es) 2017-07-11
PT2231707E (pt) 2015-03-25
KR20160105943A (ko) 2016-09-07
US20090220521A1 (en) 2009-09-03
RS53906B1 (sr) 2015-08-31
EP2754671A3 (en) 2015-07-08
NZ596409A (en) 2013-05-31
IL206715A (en) 2015-06-30
EP3118223B8 (en) 2020-04-15
ES2791333T3 (es) 2020-11-03
IL206715A0 (en) 2010-12-30
RU2013153592A (ru) 2015-06-10
KR101654678B1 (ko) 2016-09-08
EP2754671A2 (en) 2014-07-16
EP2231707A1 (en) 2010-09-29
US20150023978A1 (en) 2015-01-22
CN101983207B (zh) 2016-01-20
ZA201004973B (en) 2011-03-30
PL3118223T3 (pl) 2021-04-06
AU2008346517B2 (en) 2013-12-05
CN103724430B (zh) 2016-09-21
JP2011510616A (ja) 2011-04-07
CN103724430A (zh) 2014-04-16
US8668909B2 (en) 2014-03-11
KR20100102197A (ko) 2010-09-20

Similar Documents

Publication Publication Date Title
ES2531629T3 (es) Anticuerpos anti-MIF
Sanyal et al. A phase 2 randomized trial of survodutide in MASH and fibrosis
Lok et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos (t) ide-naive patients with chronic hepatitis B
García-Pola Vallejo et al. Anxiety and depression as risk factors for oral lichen planus
AU2012228418B2 (en) Use of low dose IL-2 for treating autoimmune - related or inflammatory disorders
US20140004080A1 (en) Use of low dose il-2 for treating autoimmune - related or inflammatory disorders
Lawitz et al. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy
AU2020203316B2 (en) Novel regimes of FXR agonists
WO2013165590A1 (en) Methods for treating idiopathic pulmonary fibrosis
BR0306732A (pt) Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico
Wang et al. Effects of extracellular histones on left ventricular diastolic function and potential mechanisms in mice with sepsis
KR20160125466A (ko) 매트릭스 메탈로프로테이나제 9에 대한 항체 및 그의 사용 방법
Kim et al. GX-I7 (rhIL-7-hyFc, efineptakin alfa), a long-acting IL-7, safely and effectively increased peripheral CD8+ and CD4+ T cells and TILs in patients with solid tumors
TW202423978A (zh) 急性呼吸衰竭之治療
Arkhipov et al. Study of macrophages in BCG granulomas in different compartments of the mononuclear phagocyte system
Li et al. Transbody against virus core protein potently inhibits hepadnavirus replication in vivo: evidence from a duck model of hepatitis B virus
Shousha et al. Generic Sofosbuvir/Ledipasvir for Treatment of Naï ve, Non-Cirrhotic, Easy to Treat Patients with Chronic Hepatitis C Genotype 4: 8 Vs. 12 Weeks of Treatment
Hernández-Oropeza et al. Pulmonary vasoreactivity and phenotypes in pulmonary arterial hypertension associated to connective tissue diseases
Tokgözoğlu et al. Two years of multidisciplinary diagnostic and therapeutic experience in patients with pulmonary arterial hypertension
Monastirli et al. Classic form of eosinophilic pustular folliculitis in an immunocompetent girl: rapid and complete resolution after low-dose oral indomethacin treatment
Ma et al. Evaluation of a Multi-disciplinary Medical Model in Vancomycin Treatment in Chinese Adult Patients: A Randomized Controlled Trial
Lee et al. Weekly low-dose docetaxel for salvage chemotherapy in pretreated elderly or poor performance status patients with non-small cell lung cancer
Chen et al. A Phase I, Randomized, Observer-Blinded, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers
Wikström et al. Ashutosh Wechalekar1, Gunnar Antoni2, Wasfi Al Azzam3, 9, Mats Bergström4, Swethajit Biswas4, 10, Chao Chen4, Joseph Cheriyan5, Matthew Cleveland4, Louise Cookson6, Paul Galette3, Robert L. Janiczek4, Raymond Y. Kwong7, Mary Ann Lukas3, Helen Millns4, Duncan Richards4, 10, Ian Schneider6, 11, Scott D. Solomon7, Jens Sörensen2, James Storey4, Douglas Thompson4, Guus van Dongen8, Danielle J. Vugts8, Anders Wall2
Monin et al. Deficient immune response following SARS-CoV-2 vaccincation in patients with hepatobiliary carcinoma